By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

After a federal judge blocked Health Secretary Robert F. Kennedy Jr.’s vaccine policies, the Justice Department has yet to ...

Total protection for when respiratory illness season hits. We may be inching toward that reality. A new paper published in ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same ...

A deadly flu surge is sweeping Australia, with doctors fearing a repeat of last year’s horror season that overwhelmed ...

Flu and Covid, including a new variant called BA.3.2, nicknamed “cicada,” are still circulating across the U.S. in 2026. How ...

GoodRx, a platform for medication savings, is tracking prescription fills for medications that treat seasonal viral respiratory infections. The tracker includes fills for: To this end, GoodRx Research ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

While the latest variant, called Cicada, carries more mutations, it’s still part of the Omicron family that emerged in 2021.

Although Covid-19 is circulating at a very low level right now, the US is just starting to contend with this sleeper branch ...